共 58 条
[1]
Ardoin S.P.(2005)The management of pediatric systemic lupus erythematosus Nature Clin Prac Rheum 1 82-92
[2]
Schanberg L.E.(1992)Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE Arthritis Rheum 35 630-640
[3]
Bombardier C.(2006)Drug insight: rituxumab in renal disease and transplantation Nature Clin Prac Nephrol 2 221-230
[4]
Gladman D.D.(2006)Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis Arthritis Rheum 54 613-620
[5]
Urowitz M.B.(2001)Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity Nature Immunol 2 764-766
[6]
Caron D.(2005)Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases Ann Rheum Dis 64 913-920
[7]
Chang C.H.(2005)B cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients Rheumatology (Oxford) 44 1542-1545
[8]
Salama A.D.(2004)B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab Arthritis Rheum 50 2580-2589
[9]
Pusey C.D.(2002)Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune hemolytic anemia in a patient with systemic lupus erythematosus Br J Hematol 116 465-467
[10]
Leandro M.J.(2004)Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus Rheumatology (Oxford) 43 244-813